RxSight Reports Q3 2026 Revenue Decline Amid Competitive Pressures and Restructuring
RxSight (RXST) reported a challenging third quarter for 2026, with total revenue falling 19% year-over-year to $24.6 million. The decline was primarily attributed to increased competitive pressures in the LAL procedure market and internal disruptions caused by a significant reorganization of the U.S. sales force. Consequently, the company reported a net loss of $16.2 million, or $0.39 per share. Despite these headwinds, the company is focusing on long-term stability through an organizational realignment aimed at reducing 2027 operating expenses and a strategic collaboration with Alcon. Management expects fourth-quarter LAL sales to show sequential growth compared to the third quarter, even as they navigate ongoing product trialing by competitors and the integration of new sales territories.
Topics: Gross Margin Compression Net Loss Revenue Decline Sales Force Expansion Strategic Partnership